France’s Sanofi said on Monday it had agreed to buy Synthorx in a cash deal worth around $2.5 billion as it seeks to beef up its immuno-oncology pipeline. Under the terms of the merger agreement, Sanofi has offered to buy all of the outstanding shares of Synthorx common stock for $68 per share in cash. “This acquisition …is aligned with our goal to build our oncology franchise with potentially practice-changing medicines and novel combinations,” Sanofi CEO Paul Hudson said in a statement.
France’s Sanofi 
